29
Participants
Start Date
December 23, 2024
Primary Completion Date
March 31, 2027
Study Completion Date
May 31, 2027
Anlotinib combined with Sintilimab
Based on the mFOLFIRINOX chemotherapy regimen, combined with the safe dose of anlotinib determined in phase Ib and sintilimab.
NOT_YET_RECRUITING
First Affiliated Hospital of Fujian Medical University, Fuzhou
RECRUITING
Fujian Provincial Hospital, Fuzhou
NOT_YET_RECRUITING
Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou
NOT_YET_RECRUITING
Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou
Fujian Provincial Hospital
OTHER